TITLE

Prolonged progression-free survival in metastatic breast cancer

AUTHOR(S)
Mayor, Susan
PUB. DATE
July 2008
SOURCE
British Journal of Hospital Medicine (17508460);Jul2008, Vol. 69 Issue 7, p378
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article highlights the study conducted by GBG-26 on the metastatic breast cancer treatment in Great Britain. The study shows that continuing treatment with Herceptin (trastuzumab) increases progression-free survival in women with advanced HER2-positive breast cancer. In addition, Professor Gunter von Minckwitz has stated that trastuzumab continues to target and shrink HER2-positive breast cancer even beyond progression.
ACCESSION #
33319446

 

Related Articles

  • De-escalation attempts for adjuvant trastuzumab: longer beats shorter. Curigliano, G.; Goldhirsch, A. // Annals of Oncology;Jul2015, Vol. 26 Issue 7, p1275 

    No abstract available.

  • 1-year trastuzumab remains standard in HER-2-positive breast cancer.  // Hem/Onc Today;8/25/2013, Vol. 14 Issue 16, p8 

    The article reports on the results of a randomized phase 3 trial which demonstrated that one-year of adjuvant trastuzumab remains the standard treatment for patients with HER-2-positive breast cancer.

  • Perjeta-Herceptin combo pack now funded in Alberta, Canada.  // PharmacoEconomics & Outcomes News;Feb2014, Issue 695, p10 

    The article reports that the Cancer Drug Benefit Program of Alberta Health Services, Canada will provide funding for a combo pack of pertuzumab and trastuzumab (Perjeta and Herceptin) drugs for patients with metastatic breast cancer.

  • Toxicity decreased with trastuzumab-DM1 vs. trastuzumab plus docetaxel. Harris, Jason; Southall, Jennifer // Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p18 

    The article discusses research being done on the effectiveness of trastuzumab plus docetaxel and trastuzumab-DM1 for treatment of patients with HER2-positive metastatic breast cancer, which references a study by Edith Perez and colleagues presented at the 35th European Society for Medical...

  • Breast cancer's newest hope. Aschwanden, Christie; Freinkel, Susan; Kanigel, Rachele; Strauss, Evelyn // Health (Time Inc. Health);Sep98, Vol. 12 Issue 6, p27 

    Focuses on the use of the protein Herceptin to combat breast cancer. Reference to other breast cancer studies; How Herceptin functions; Statements from oncologist Mark Pegram of the University of California at Los Angeles.

  • 1-year trastuzumab remains standard in HER-2-positive breast cancer.  // Hem/Onc Today;8/25/2013, Vol. 14 Issue 16, p8 

    The article reports on the results of a randomized phase 3 trial which demonstrated that one-year of adjuvant trastuzumab remains the standard treatment for patients with HER-2-positive breast cancer.

  • Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2. McKeage, K.; Perry, C.M. // Drugs;2002, Vol. 62 Issue 1, p209 

    Trastuzumab is a humanised monoclonal antibody developed to target the HER2 receptor which is overexpressed by some cancer cells, including 25 to 30% of breast cancers. Binding with high affinity to the extracellular domain of HER2, trastuzumab inhibits the proliferation of tumour cells that...

  • Herceptin 12-month standard remains. Topham-Kindley, Liane // New Zealand Doctor;11/7/2012, p16 

    The article discusses the results of the new studies concerning the optimal duration of the Herceptin therapy in HER2-positive women with early breast cancer which confirm the adoption of 12-month medical standard in New Zealand.

  • Pertuzumab improved PFS when given with trastuzumab, chemotherapy. Baselga, J. // Hem/Onc Today;12/25/2011, Vol. 12 Issue 24, p50 

    The article reports on the capacity of the triple drug combination of pertuzumab, trastuzumab and docetaxel to improve progression-free survival (PFS) in patients with HER-2-positive metastatic or locally recurrent breast cancer, according to results of a study.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics